Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis

Pediatric Pulmonology

Volumn 43, Issue 6, 2008, Pages 607-610

  Zirbes, Jacquelyn M ^a   Milla, Carlos E ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Allergic bronchopulmonary aspergillosis; Cystic fibrosis; Omalizumab

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN E; ITRACONAZOLE; OMALIZUMAB; PREDNISONE; STEROID;

ADOLESCENT; ANAMNESIS; ARTICLE; ASPERGILLUS; BRONCHOPULMONARY ASPERGILLOMA; CASE REPORT; CLINICAL FEATURE; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE CONTROL; DISEASE EXACERBATION; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIPHYSIOLYSIS; GASTROESOPHAGEAL REFLUX; HUMAN; MAINTENANCE THERAPY; MALE; OSTEOPOROSIS; PRICK TEST; PRIORITY JOURNAL; RECURRENT DISEASE; SCHOOL CHILD; SHORT STATURE; SPIROMETRY; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; CHILD; CYSTIC FIBROSIS; GLUCOCORTICOIDS; HUMANS; MALE; PREDNISONE;

EID: 44949162045     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20804     Document Type: Article

References (13)

1. Registry, C.F.F.P., 2006 Annual Data Report to the Center Directors 2007: Bethesda, MD.
2. Knutsen ACB, Chauhan B, Slavin RG. Cell mediated immunity in allergic bronchopulmonary aspergillosis. Immunol Allergy Clin N Am 1998;18:25.
3. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, Skov M, Maish W, Mastella G. Allergic bronchopulmonary aspergillosis in cystic fibrosis - State of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003;37:S225-S264.
4. Rosenstein BJ, Eigen H. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 1991;87:245-246.
5. Berger WE. Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease. Ann Allergy Asthma Immunol 88:152-160; quiz 161-162.
6. Buhl R, Soler M, Matz J, Townley R, O'Brien J, Noga O, Champain K, Fox H, Thirlwell J, Delia Cioppa G. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20:73-78.
7. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-190.
8. Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving Omalizumab (Xolair) therapy. J Immunol Methods 2005;303:81-91.
9. Slavin RG, Gleich GJ, Hutcheson PS, Kephardt GM, Knutsen AP, Tsai CC. Localization of IgE to lung germinal lymphoid follicles in a patient with allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1992;90:1006-1008.
10. Patterson R, Greenberger PA, Halwig JM, Liotta JL, Roberts M. Allergic bronchopulmonary aspergillosis: natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med 1986;146:916-918.
11. Lin H, Boesel K, Griffith DT, Prussin C, Foster B, Romero FA, Townley R, Casale TB. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J Allergy Clin Immunol 2004;113:297-302.
12. Judson MA, Stevens DA. Current pharmacotherapy of allergic bronchopulmonary aspergillosis. Expert Opin Pharmacother 2001;2:1065-1071.
13. Leon EE, Craig TJ. Antifungals in the treatment of allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol 1999;82:511-517.